Shigenobu Kanba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shigenobu Kanba has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Kazuo Yamada
Department of Psychiatry, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishi-ogu, Arakawa-ku, Tokyo 116-8567, Japan
7 shared publications Masahiro Asai
5 shared publications- Takahiro A. Kato
Department of Psychiatry Hokkaido University Graduate School of Medicine Sapporo Japan
5 shared publications Hiroko Mizushima
4 shared publications- Tadafumi Kato
Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo, Japan
4 shared publications - Eri Arita
Japan/Asia Clinical Development 2, Astellas Pharma Inc.; 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan
3 shared publications
Latest Publications
- Open Access
- 26 June 2019
- Published by Springer Nature in BMC Psychiatry
- Vol. 19 (1) , 1-10
Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression
In an 8-week, randomized, placebo-controlled, double-blind study, an extended-release formulation of quetiapine, quetiapine XR, demonstrated efficacy and safety in Japanese patients with bipolar depression. Bipolar disorder is a chronic disease requiring continuous treatment. This was a long-term (52-week), open-label, non-controlled extension study to evaluate the long-term safety and efficacy of quetiapine XR in Japanese patients with bipolar depression who had previously completed the initial 8-week double-blind study. Efficacy was determined by the Montgomery–Åsberg Depression Rating Scale (MADRS), Hamilton Depression Scale 17-item (HAM-D17), and Clinical Global Impressions-Bipolar scale (CGI-BP). Safety evaluations included analysis of adverse events, clinical laboratory measures, vital signs, Drug-induced Extrapyramidal Symptoms Scale, Young Mania Rating Scale, and the Columbia Suicide Severity Rating Scale. The mean (SD) MADRS total score decreased from 30.9 (6.9) at baseline to 16.1 (10.6) at week 8, and eventually to 9.1 (8.7) at week 52. The sustained efficacy of quetiapine XR treatment was also shown using HAM-D17 total scores, CGI-BP-Severity and Change evaluations. The most common adverse events were somnolence, nasopharyngitis, and thirst. Long-term treatment with quetiapine XR caused no substantial changes in the safety profiles, including clinical laboratory parameters, and no new safety concerns were identified. The efficacy of quetiapine XR was sustained long-term and no new safety concerns were identified in Japanese patients with bipolar depression. ClinicalTrials.gov Registration: NCT01725308. Date of registration; 12th November 2012 (retrospectively registered).
- 26 June 2019
- Published by Springer Nature in BMC Psychiatry
- Vol. 19 (1) , 1-10
Open AccessLong-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression
In an 8-week, randomized, placebo-controlled, double-blind study, an extended-release formulation of quetiapine, quetiapine XR, demonstrated efficacy and safety in Japanese patients with bipolar depression. Bipolar disorder is a chronic disease requiring continuous treatment. This was a long-term (52-week), open-label, non-controlled extension study to evaluate the long-term safety and efficacy of quetiapine XR in Japanese patients with bipolar depression who had previously completed the initial 8-week double-blind study. Efficacy was determined by the Montgomery–Åsberg Depression Rating Scale (MADRS), Hamilton Depression Scale 17-item (HAM-D17), and Clinical Global Impressions-Bipolar scale (CGI-BP). Safety evaluations included analysis of adverse events, clinical laboratory measures, vital signs, Drug-induced Extrapyramidal Symptoms Scale, Young Mania Rating Scale, and the Columbia Suicide Severity Rating Scale. The mean (SD) MADRS total score decreased from 30.9 (6.9) at baseline to 16.1 (10.6) at week 8, and eventually to 9.1 (8.7) at week 52. The sustained efficacy of quetiapine XR treatment was also shown using HAM-D17 total scores, CGI-BP-Severity and Change evaluations. The most common adverse events were somnolence, nasopharyngitis, and thirst. Long-term treatment with quetiapine XR caused no substantial changes in the safety profiles, including clinical laboratory parameters, and no new safety concerns were identified. The efficacy of quetiapine XR was sustained long-term and no new safety concerns were identified in Japanese patients with bipolar depression. ClinicalTrials.gov Registration: NCT01725308. Date of registration; 12th November 2012 (retrospectively registered).
- 17 September 2018
- Published by Springer Nature in Psychopharmacology
- Vol. 235 (10) , 3079-3080
Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
The original version of this article contained a mistake in Table 5. Correct version is presented here.
- 17 September 2018
- Published by Springer Nature in Psychopharmacology
- Vol. 235 (10) , 3079-3080
Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
The original version of this article contained a mistake in Table 5. Correct version is presented here.
- Open Access
- 1 August 2018
- Published by Springer Nature in Psychopharmacology
- Vol. 235 (10) , 2859-2869
Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
Rationale Quetiapine fumarate is an atypical antipsychotic indicated for various mental disorders, but it has not been studied in Japanese patients with bipolar depression. Objectives To evaluate the efficacy and safety of quetiapine XR (extended release) in Japanese patients with bipolar depression. Methods In this multi-center, randomized, double-blind, placebo-controlled, fixed-dose study of 431 Japanese adults with bipolar I or II disorder, efficacy was determined by analyzing the mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary end points included MADRS response and remission rates, Hamilton Depression Scale 17-Item (HAM-D17), and Clinical Global Impressions-Bipolar (CGI-BP) scale scores. Safety was determined by monitoring adverse events and clinical assessments. Results This study revealed a statistically significantly greater decrease in MADRS total score after 8 weeks of quetiapine XR 300 mg/day monotherapy compared with placebo (− 12.6 vs. − 10.1; p = 0.034). There were also improvements in MADRS response (44.1 vs. 35.6%) and remission (38.0 vs. 26.6%) rates as well as in HAM-D17 and CGI-BP scale scores compared with placebo. In the subgroup analysis of patients with bipolar I or II disorder, the adjusted mean changes in MADRS total score compared to placebo were − 2.3 and − 2.1, respectively. Adverse events occurred in 149 patients (83.2%) receiving quetiapine XR 300 mg/day and in 81 patients (45.8%) receiving placebo. The most common adverse events were somnolence and thirst, which is consistent with the previously reported safety profile. Conclusions Once-daily monotherapy with quetiapine XR is an effective and well-tolerated treatment for bipolar depression in Japanese patients.
- 1 August 2018
- Published by Springer Nature in Psychopharmacology
- Vol. 235 (10) , 2859-2869
Open AccessMulti-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
Rationale Quetiapine fumarate is an atypical antipsychotic indicated for various mental disorders, but it has not been studied in Japanese patients with bipolar depression. Objectives To evaluate the efficacy and safety of quetiapine XR (extended release) in Japanese patients with bipolar depression. Methods In this multi-center, randomized, double-blind, placebo-controlled, fixed-dose study of 431 Japanese adults with bipolar I or II disorder, efficacy was determined by analyzing the mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary end points included MADRS response and remission rates, Hamilton Depression Scale 17-Item (HAM-D17), and Clinical Global Impressions-Bipolar (CGI-BP) scale scores. Safety was determined by monitoring adverse events and clinical assessments. Results This study revealed a statistically significantly greater decrease in MADRS total score after 8 weeks of quetiapine XR 300 mg/day monotherapy compared with placebo (− 12.6 vs. − 10.1; p = 0.034). There were also improvements in MADRS response (44.1 vs. 35.6%) and remission (38.0 vs. 26.6%) rates as well as in HAM-D17 and CGI-BP scale scores compared with placebo. In the subgroup analysis of patients with bipolar I or II disorder, the adjusted mean changes in MADRS total score compared to placebo were − 2.3 and − 2.1, respectively. Adverse events occurred in 149 patients (83.2%) receiving quetiapine XR 300 mg/day and in 81 patients (45.8%) receiving placebo. The most common adverse events were somnolence and thirst, which is consistent with the previously reported safety profile. Conclusions Once-daily monotherapy with quetiapine XR is an effective and well-tolerated treatment for bipolar depression in Japanese patients.
- Open Access
- 17 January 2017
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 16 (1) , 1-8
A pilot study exploring the association of morphological changes with 5-HTTLPR polymorphism in OCD patients
Clinical and pharmacological studies of obsessive-compulsive disorder (OCD) have suggested that the serotonergic systems are involved in the pathogenesis, while structural imaging studies have found some neuroanatomical abnormalities in OCD patients. In the etiopathogenesis of OCD, few studies have performed concurrent assessment of genetic and neuroanatomical variables. We carried out a two-way ANOVA between a variable number of tandem repeat polymorphisms (5-HTTLPR) in the serotonin transporter gene and gray matter (GM) volumes in 40 OCD patients and 40 healthy controls (HCs). We found that relative to the HCs, the OCD patients showed significant decreased GM volume in the right hippocampus, and increased GM volume in the left precentral gyrus. 5-HTTLPR polymorphism in OCD patients had a statistical tendency of stronger effects on the right frontal pole than those in HCs. Our results showed that the neuroanatomical changes of specific GM regions could be endophenotypes of 5-HTTLPR polymorphism in OCD.
- 17 January 2017
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 16 (1) , 1-8
Open AccessA pilot study exploring the association of morphological changes with 5-HTTLPR polymorphism in OCD patients
Clinical and pharmacological studies of obsessive-compulsive disorder (OCD) have suggested that the serotonergic systems are involved in the pathogenesis, while structural imaging studies have found some neuroanatomical abnormalities in OCD patients. In the etiopathogenesis of OCD, few studies have performed concurrent assessment of genetic and neuroanatomical variables. We carried out a two-way ANOVA between a variable number of tandem repeat polymorphisms (5-HTTLPR) in the serotonin transporter gene and gray matter (GM) volumes in 40 OCD patients and 40 healthy controls (HCs). We found that relative to the HCs, the OCD patients showed significant decreased GM volume in the right hippocampus, and increased GM volume in the left precentral gyrus. 5-HTTLPR polymorphism in OCD patients had a statistical tendency of stronger effects on the right frontal pole than those in HCs. Our results showed that the neuroanatomical changes of specific GM regions could be endophenotypes of 5-HTTLPR polymorphism in OCD.
- 31 August 2016
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 70 (9) , 371-393
Current viewpoints on DSM‐5 in Japan
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) was published in 2013, and its official Japanese version was published in 2014. The Japanese Government uses classifications from the 10th revision of the I nternational C lassification of D iseases (ICD‐10) to categorize disorders and determine treatment fees. However, since the publication of the DSM‐III, the use of the DSM system has become prevalent in research and educational settings in Japan. In addition to traditional psychiatry, both the ICD and the DSM are taught by many Japanese medical schools, and virtually all clinical research and trials refer to the DSM to define targeted disorders. Amid the current backdrop in which the reputation of the DSM‐5 is being established, the editorial board of P sychiatry and C linical N eurosciences has asked Japanese experts across 12 specialties to examine the structure of the DSM‐5, including the following categories: Neurodevelopmental Disorders, Schizophrenia Spectrum Disorders, Major Depression, Bipolar Disorders, Obsessive–Compulsive Disorders, Somatic Symptom Disorder, Eating Disorders, Substance‐Related and Addictive Disorders, Gender Dysphoria, and Neurocognitive Disorders. Although opinions were only obtained from these selected experts, we believe that we have succeeded, to a certain extent, in presenting views that are representative of each specialty.
- 31 August 2016
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 70 (9) , 371-393
Current viewpoints on DSM‐5 in Japan
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) was published in 2013, and its official Japanese version was published in 2014. The Japanese Government uses classifications from the 10th revision of the I nternational C lassification of D iseases (ICD‐10) to categorize disorders and determine treatment fees. However, since the publication of the DSM‐III, the use of the DSM system has become prevalent in research and educational settings in Japan. In addition to traditional psychiatry, both the ICD and the DSM are taught by many Japanese medical schools, and virtually all clinical research and trials refer to the DSM to define targeted disorders. Amid the current backdrop in which the reputation of the DSM‐5 is being established, the editorial board of P sychiatry and C linical N eurosciences has asked Japanese experts across 12 specialties to examine the structure of the DSM‐5, including the following categories: Neurodevelopmental Disorders, Schizophrenia Spectrum Disorders, Major Depression, Bipolar Disorders, Obsessive–Compulsive Disorders, Somatic Symptom Disorder, Eating Disorders, Substance‐Related and Addictive Disorders, Gender Dysphoria, and Neurocognitive Disorders. Although opinions were only obtained from these selected experts, we believe that we have succeeded, to a certain extent, in presenting views that are representative of each specialty.
- 1 December 2015
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 69 (12) , 791-793
Acknowledgments
- 1 December 2015
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 69 (12) , 791-793
Acknowledgments
- 13 July 2015
- Published by American Psychological Association (APA)
Hikikomori Assessment Interview
- 4 January 2015
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 69 (1) , 1-2
Conquering depression
- 4 January 2015
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 69 (1) , 1-2
Conquering depression
- 1 November 2014
- Published by Elsevier in The Lancet Psychiatry
- Vol. 1 (6) , 418-419
Bipolar treatment efficacy – Authors' reply
- 1 November 2014
- Published by Elsevier in The Lancet Psychiatry
- Vol. 1 (6) , 418-419
Bipolar treatment efficacy – Authors' reply
- 1 October 2014
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 275 (1) , 120
Modeling brain diseases with direct induction technology of ramified microglia-like (iMG) cells from human monocytes
- 1 October 2014
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 275 (1) , 120
Modeling brain diseases with direct induction technology of ramified microglia-like (iMG) cells from human monocytes